MPE comments on the European Medicines Agency’s policy on the handling of competing interests of scientific committees’ members and experts
Last week Myeloma Patients Europe (MPE) provided feedback, as part of a public consultation, on the new European Medicines Agency (EMA) policy on the handling of competing interests of scientific committees’ members and experts. The new policy increases restrictions for the participation of experts, including patient experts, in the EMA procedures assessing specific medical products.…